SB-656104-A, a novel selective 5-HT7 receptor antagonist, modulates REM sleep in rats.
paper
Cited
Public
Unavailable
- Authors
- Thomas, David R; Melotto, Sergio; Massagrande, Mario; Gribble, Andrew D; Jeffrey, Phillip; Stevens, Alexander J; Deeks, Nigel J; Eddershaw, Peter J; Fenwick, Susan H; Riley, Graham; Stean, Tania; Scott, Claire M; Hill, Matthew J; Middlemiss, Derek N; Hagan, Jim J; Price, Gary W; Forbes, Ian T
- Year
- 2003
- Journal
- British journal of pharmacology
- PMID
- 12812993
- DOI
- 10.1038/sj.bjp.0705290
- PMCID
- PMC1573887
1 (6-((R)-2-[2-[4-(4-Chloro-phenoxy)-piperidin-1-yl]-ethyl]-pyrrolidine-1-sulphonyl)-1H-indole hydrochloride) (SB-656104-A), a novel 5-hydroxytryptamine (5-HT(7)) receptor antagonist, potently inhibited [(3)H]-SB-269970 binding to the human cloned 5-HT(7(a)) (pK(i) 8.7+/-0.1) and 5-HT(7(b)) (pK(i) 8.5+/-0.2) receptor variants and the rat native receptor (pK(i) 8.8+/-0.2). The compound displayed at least 30-fold selectivity for the human 5-HT(7(a)) receptor versus other human cloned 5-HT receptors apart from the 5-HT(1D) receptor ( approximately 10-fold selective). 2 SB-656104-A antagonised competitively the 5-carboxamidotryptamine (5-CT)-induced accumulation of cyclic AMP in h5-HT(7(a))/HEK293 cells with a pA(2) of 8.5. 3 Following a constant rate iv infusion to steady state in rats, SB-656104 had a blood clearance (CL(b)) of 58+/-6 ml min(-1) kg(-1) and was CNS penetrant with a steady-state brain : blood ratio of 0.9 : 1. Following i.p. administration to rats (10 mg kg(-1)), the compound displayed a t(1/2) of 1.4 h with mean brain and blood concentrations (at 1 h after dosing) of 0.80 and 1.0 micro M, respectively. 4 SB-656104-A produced a significant reversal of the 5-CT-induced hypothermic effect in guinea pigs, a pharmacodynamic model of 5-HT(7) receptor interaction in vivo (ED(50) 2 mg kg(-1)). 5 SB-656104-A, administered to rats at the beginning of the sleep period (CT 0), significantly increased the latency to onset of rapid eye movement (REM) sleep at 30 mg kg(-1) i.p. (+93%) and reduced the total amount of REM sleep at 10 and 30 mg kg(-1) i.p. with no significant effect on the latency to, or amount of, non-REM sleep. SB-269970-A produced qualitatively similar effects in the same study. 6 In summary, SB-656104-A is a novel 5-HT(7) receptor antagonist which has been utilised in the present study to provide further evidence for a role for 5-HT(7) receptors in the modulation of REM sleep.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Mazindol Immediate-Release/Sustained-Release (IR/SR): A 50-Year Legacy of Multifaceted Mechanisms and Emerging Therapeutic Potential. | Konofal E et al. | — | 2026 | → |
| 5-HT<sub>7</sub>R Deficiency Alleviates ADP-Heptose-Induced Cognitive Impairment via Inhibiting Ferroptosis and Neuroinflammation in Mice. | Zou X et al. | — | 2025 | → |
| Protective Effects of <i>Curcuma longa L</i>. on Corticosterone-Induced Neurotoxicity and Anti-Depression-Like Behavior: Involvement of NMDA and 5-HT<sub>7A</sub> Receptors. | Oh KN et al. | — | 2025 | → |
| The 5-HT7 receptor system as a treatment target for mood and anxiety disorders: A systematic review. | Gottlieb N et al. | — | 2023 | → |
| Trazodone once-a-day: A formula for addressing challenges in antidepressant safety and tolerability. | Goldberg JF et al. | — | 2023 | → |
| Difference in the regulation of biological rhythm symptoms of Major depressive disorder between escitalopram and mirtazapine. | Huang H et al. | — | 2022 | → |
| Hyperthermia and Serotonin: The Quest for a "Better Cyproheptadine". | Petroianu GA | — | 2022 | → |
| The Roles of Serotonin in Neuropsychiatric Disorders. | Pourhamzeh M et al. | — | 2022 | → |
| 5-HT Receptors and Temperature Homeostasis. | Voronova IP | — | 2021 | → |
| Discovery of Nonracemic Amisulpride to Maximize Benefit/Risk of 5-HT7 and D2 Receptor Antagonism for the Treatment of Mood Disorders. | Hopkins SC et al. | — | 2021 | → |
| International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. | Barnes NM et al. | — | 2021 | → |
| Structure-activity relationships of serotonin 5-HT<sub>7</sub> receptors ligands: A review. | Thirumaran SL et al. | — | 2019 | → |
| Asenapine modulates mood-related behaviors and 5-HT<sub>1A/7</sub> receptors-mediated neurotransmission. | Delcourte S et al. | — | 2017 | → |
| Potential functional and pathological side effects related to off-target pharmacological activity. | Lynch JJ et al. | — | 2017 | → |
| Chronic mild stress-induced alterations of clock gene expression in rat prefrontal cortex: modulatory effects of prolonged lurasidone treatment. | Calabrese F et al. | — | 2016 | → |
| N-Alkylated arylsulfonamides of (aryloxy)ethyl piperidines: 5-HT(7) receptor selectivity versus multireceptor profile. | Canale V et al. | — | 2016 | → |
| Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties. | Canale V et al. | — | 2016 | → |
| Whole genome sequencing of a dizygotic twin suggests a role for the serotonin receptor HTR7 in autism spectrum disorder. | Helsmoortel C et al. | — | 2016 | → |
| Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 2, pharmacological interactions in rodents suggest a role of serotonin-3 receptor antagonism. | Leiser SC et al. | — | 2015 | → |
| Serotonin 7 Receptor Variants Are Not Associated with Response to Second-Generation Antipsychotics in Japanese Schizophrenia Patients. | Takekita Y et al. | — | 2015 | → |
| Targeting the Serotonin 5-HT7 Receptor in the Search for Treatments for CNS Disorders: Rationale and Progress to Date. | Nikiforuk A | — | 2015 | → |
| The role of the serotonin receptor subtypes 5-HT1A and 5-HT7 and its interaction in emotional learning and memory. | Stiedl O et al. | — | 2015 | → |
| 3D QSAR based design of novel oxindole derivative as 5HT7 inhibitors. | Chitta A et al. | — | 2014 | → |
| 5-HT7 receptors as modulators of neuronal excitability, synaptic transmission and plasticity: physiological role and possible implications in autism spectrum disorders. | Ciranna L et al. | — | 2014 | → |
| Genome-wide association discoveries of alcohol dependence. | Zuo L et al. | — | 2014 | → |
| Interplay between serotonin 5-HT1A and 5-HT7 receptors in depressive disorders. | Naumenko VS et al. | — | 2014 | → |
| Novel N-biphenyl-2-ylmethyl 2-methoxyphenylpiperazinylalkanamides as 5-HT7R antagonists for the treatment of depression. | Kim Y et al. | — | 2014 | → |
| Serotonin modulation of macrophage polarization: inflammation and beyond. | de Las Casas-Engel M et al. | — | 2014 | → |
| Systemic administration and local microinjection into the central nervous system of the 5-HT(7) receptor agonist LP-211 modify the sleep-wake cycle in the rat. | Monti JM et al. | — | 2014 | → |
| The 5-HT7 receptor as a potential target for treating drug and alcohol abuse. | Hauser SR et al. | — | 2014 | → |
| Peripheral 5-HT7 receptors as a new target for prevention of lung injury and mortality in septic rats. | Cadirci E et al. | — | 2013 | → |
| Sensitization of restraint-induced corticosterone secretion after chronic restraint in rats: involvement of 5-HT₇ receptors. | García-Iglesias BB et al. | — | 2013 | → |
| The effects of combining serotonin reuptake inhibition and 5-HT7 receptor blockade on circadian rhythm regulation in rodents. | Westrich L et al. | — | 2013 | → |
| The serotonin receptor 7 promotes neurite outgrowth via ERK and Cdk5 signaling pathways. | Speranza L et al. | — | 2013 | → |
| 5-HT7R/G12 signaling regulates neuronal morphology and function in an age-dependent manner. | Kobe F et al. | — | 2012 | → |
| Microinjection of the 5-HT7 receptor antagonist SB-269970 into the rat brainstem and basal forebrain: site-dependent effects on REM sleep. | Monti JM et al. | — | 2012 | → |
| Modulatory effects of two novel agonists for serotonin receptor 7 on emotion, motivation and circadian rhythm profiles in mice. | Adriani W et al. | — | 2012 | → |
| Review of pharmacological treatment in mood disorders and future directions for drug development. | Li X et al. | — | 2012 | → |
| Stress- and antidepressant treatment-induced modifications of 5-HT₇ receptor functions in the rat brain. | Tokarski K et al. | — | 2012 | → |
| Translational evaluation of JNJ-18038683, a 5-hydroxytryptamine type 7 receptor antagonist, on rapid eye movement sleep and in major depressive disorder. | Bonaventure P et al. | — | 2012 | → |
| Effects of the 5-HT₆ receptor antagonists SB-399885 and RO-4368554 and of the 5-HT(2A) receptor antagonist EMD 281014 on sleep and wakefulness in the rat during both phases of the light-dark cycle. | Monti JM et al. | — | 2011 | → |
| Evidence for in vivo thermosensitivity of serotonergic neurons in the rat dorsal raphe nucleus and raphe pallidus nucleus implicated in thermoregulatory cooling. | Hale MW et al. | — | 2011 | → |
| Genome-wide association study of theta band event-related oscillations identifies serotonin receptor gene HTR7 influencing risk of alcohol dependence. | Zlojutro M et al. | — | 2011 | → |
| Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy. | Mnie-Filali O et al. | — | 2011 | → |
| Role of the 5-HT7 receptor in the central nervous system: from current status to future perspectives. | Matthys A et al. | — | 2011 | → |
| Serotonin 5-HT7 receptor agents: Structure-activity relationships and potential therapeutic applications in central nervous system disorders. | Leopoldo M et al. | — | 2011 | → |
| The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone. | Horisawa T et al. | — | 2011 | → |
| 5-HT(7) receptor modulators: a medicinal chemistry survey of recent patent literature (2004 - 2009). | Leopoldo M et al. | — | 2010 | → |
| Antipsychotic drug development. | Kim DH et al. | — | 2010 | → |
| Neural mechanisms mediating circadian phase resetting by activation of 5-HT(7) receptors in the dorsal raphe: roles of GABAergic and glutamatergic neurotransmission. | Duncan MJ et al. | — | 2010 | → |
| Phe369(7.38) at human 5-HT(7) receptors confers interspecies selectivity to antagonists and partial agonists. | Varin T et al. | — | 2010 | → |
| 5-HT7 receptor deletion enhances REM sleep suppression induced by selective serotonin reuptake inhibitors, but not by direct stimulation of 5-HT1A receptor. | Shelton J et al. | — | 2009 | → |
| Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. | Abbas AI et al. | — | 2009 | → |
| Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia. | Kim DH et al. | — | 2009 | → |
| Constitutive Gs-mediated, but not G12-mediated, activity of the 5-hydroxytryptamine 5-HT7(a) receptor is modulated by the palmitoylation of its C-terminal domain. | Kvachnina E et al. | — | 2009 | → |
| Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. | Millan MJ | — | 2009 | → |
| The 5-HT7 receptor and disorders of the nervous system: an overview. | Hedlund PB | — | 2009 | → |
| 5-HT(7) receptors in the modulation of cognitive processes. | Cifariello A et al. | — | 2008 | → |
| Assessing the neuronal serotonergic target-based antidepressant stratagem: impact of in vivo interaction studies and knockout models. | Rajkumar R et al. | — | 2008 | → |
| Effect of 5-HT(7) antagonist SB-269970 in the modulation of working and reference memory in the rat. | Gasbarri A et al. | — | 2008 | → |
| Inactivation of the 5-HT(7) receptor partially blocks phencyclidine-induced disruption of prepulse inhibition. | Semenova S et al. | — | 2008 | → |
| Serotonin receptors. | Nichols DE et al. | — | 2008 | → |
| The serotonin 5-HT7 receptor agonist LP-44 microinjected into the dorsal raphe nucleus suppresses REM sleep in the rat. | Monti JM et al. | — | 2008 | → |
| 5-HT7, neurogenesis and antidepressants: a promising therapeutic axis for treating depression. | Nandam LS et al. | — | 2007 | → |
| Expression of 5-HT7 receptor mRNA in the hamster brain: effect of aging and association with calbindin-D28K expression. | Duncan MJ et al. | — | 2007 | → |
| Molecular targets for treating cognitive dysfunction in schizophrenia. | Gray JA et al. | — | 2007 | → |
| Rapid eye movement (REM) sleep: an endophenotype for depression. | Modell S et al. | — | 2007 | → |
| Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents. | Bonaventure P et al. | — | 2007 | → |
| Structure of the human 5-HT7 receptor gene and characterization of its promoter region. | Laenen K et al. | — | 2007 | → |
| The 5-HT7 receptor: role in novel object discrimination and relation to novelty-seeking behavior. | Ballaz SJ et al. | — | 2007 | → |
| The 5HT(7) receptor subtype is involved in the regulation of female sexual behaviour in the rat. | Siddiqui A et al. | — | 2007 | → |
| The neurobiological characteristics of rapid eye movement (REM) sleep are candidate endophenotypes of depression, schizophrenia, mental retardation and dementia. | Gottesmann C et al. | — | 2007 | → |
| Accurate prediction of the blood-brain partitioning of a large set of solutes using ab initio calculations and genetic neural network modeling. | Hemmateenejad B et al. | — | 2006 | → |
| Homeostatic regulation of sleep in a genetic model of depression in the mouse: effects of muscarinic and 5-HT1A receptor activation. | Popa D et al. | — | 2006 | → |
| Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. | Millan MJ | — | 2006 | → |
| 5-HT7 receptor inhibition and inactivation induce antidepressantlike behavior and sleep pattern. | Hedlund PB et al. | — | 2005 | → |
| 5-HT7 receptor is coupled to G alpha subunits of heterotrimeric G12-protein to regulate gene transcription and neuronal morphology. | Kvachnina E et al. | — | 2005 | → |
| Central 5-HT7 receptors are critical for reflex activation of cardiac vagal drive in anaesthetized rats. | Kellett DO et al. | — | 2005 | → |
| Genetic knockout and pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depression. | Guscott M et al. | — | 2005 | → |
| Vagal control of the heart: central serotonergic (5-HT) mechanisms. | Jordan D | — | 2005 | → |
| Autoradiographic distribution of 5-HT7 receptors in the human brain using [3H]mesulergine: comparison to other mammalian species. | Martín-Cora FJ et al. | — | 2004 | → |
| Possible role for the 5-HT1A receptor in the behavioral effects of REM sleep deprivation on free-operant avoidance responding in rat. | Harvey MT et al. | — | 2004 | → |
| Radioligand binding analysis of knockout mice reveals 5-hydroxytryptamine(7) receptor distribution and uncovers 8-hydroxy-2-(di-n-propylamino)tetralin interaction with alpha(2) adrenergic receptors. | Bonaventure P et al. | — | 2004 | → |
| Evidence for the involvement of central 5-HT7 receptors in the micturition reflex in anaesthetized female rats. | Read KE et al. | — | 2003 | → |
| Serotonin receptors: guardians of stable breathing. | Richter DW et al. | — | 2003 | → |